Sancilio and Company, Inc.: Developing Good Science Into Great Medicine

Published Online: Wednesday, August 29, 2012
Follow Pharmacy_Times:

Sancilio and Company, Inc., (SCI) is a vertically integrated biopharmaceutical company founded by Fred Sancilio, PhD, in 2007 and headquartered in Riviera Beach, Florida. We are uniquely positioned in the marketplace, leveraging our long-term relationships for quality products with demand in both the retail and institutional segments.

Sancilio and Company is an emerging generic pharmaceutical company that specializes in the development, manufacture, and sale of cardiovascular, dental, and women’s health products. Product offerings include Ocean Blue® Professional Omega-3 2100™ , which contains 2100 mg of omega-3 per serving, chewable and liquid prescription sodium fluoride supplements for the prevention of cavities in children, and prescription chewable prenatal vitamins for women who are pregnant or may become pregnant. We have a robust product pipeline utilizing a state-of-the-art manufacturing facility, with several products in various stages of development.






Our Florida-based research laboratories are staffed with highly qualified and experienced scientists, and our fully operational cGMP production facilities enable us to manufacture products that are then sold through our domestic and international distribution channels. The SCI team currently consists of approximately 70 employees, including 5 PhDs.

All Sancilio products are manufactured in the United States.

Additional information about SCI can be found at www.sancilio.com and www.oceanblueprofessional.com.

Related Articles
Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure.
Patients with chronic cardiovascular disease who receive automated reminders for their prescription blood pressure and cholesterol medications are more likely to refill those drugs.
A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
Latest Issues
$auto_registration$